



Tumor-targeting *Salmonella typhimurium* A1-R overcomes nab-paclitaxel resistance in a cervical cancer PDOX mouse model

Kentaro Miyake^{1,2,3} · Takuya Murata⁴ · Takashi Murakami³ · Ming Zhao¹ · Tasuku Kiyuna^{1,2} · Kei Kawaguchi^{1,2} · Kentaro Igarashi^{1,2} · Masuyo Miyake^{1,2,3} · Thinzar M. Lwin² · Chihiro Hozumi⁵ · Shin Komatsu⁵ · Takashi Kikuchi⁵ · Michael Bouvet² · Koichiro Shimoya⁴ · Shree Ram Singh⁶  · Itaru Endo³ · Robert M. Hoffman^{1,2}

Received: 26 October 2018 / Accepted: 4 March 2019 / Published online: 5 April 2019
© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Abstract

Purpose Cervical cancer is a recalcitrant disease. To help overcome this problem, we previously established a patient-derived orthotopic xenograft (PDOX) model of cervical cancer. In the previous study, we found the tumor to be resistant to nab-paclitaxel (nab-PTX). We also previously developed the tumor-targeting bacteria *Salmonella typhimurium* A1-R (*S. typhimurium* A1-R). The aim of the present study was to investigate the efficacy of *S. typhimurium* A1-R to overcome nab-PTX resistance in the cervical cancer PDOX model.

Methods Cervical-cancer tumor fragments were implanted orthotopically into the neck of the uterus of nude mice. The cervical-cancer PDOX models were randomized into the following four groups after the tumor volume reached 60 mm³: G1: untreated group; G2: nab-PTX (i.v., 10 mg/kg, biweekly, 3 weeks); G3: *Salmonella typhimurium* A1-R (i.v., 5 × 10⁷ CFU/body, weekly, 3 weeks); G4: nab-PTX combined with *Salmonella typhimurium* A1-R (nab-PTX, 10 mg/kg, i.v., biweekly, 3 weeks; *S. typhimurium* A1-R, 5 × 10⁷ CFU/body, i.v., weekly, 3 weeks). Each group comprised eight mice. All mice were sacrificed on day 22. Tumor volume was measured on day 0 and day 22. Body weight was measured twice a week.

Results Nab-PTX and *Salmonella typhimurium* A1-R did not show significant efficacy as monotherapy compared to the control group ($P=0.564$ and $P=0.120$, respectively). In contrast, nab-PTX combined with *Salmonella typhimurium* A1-R significantly suppressed tumor growth compared to the untreated control group and nab-PTX group ($P<0.001$ and $P=0.026$, respectively).

Conclusions *Salmonella typhimurium* A1-R has potential future clinical application to overcome drug resistance in cervical cancer.

Keywords Cervical cancer · *S. typhimurium* A1-R · Patient-derived orthotopic xenograft · Nude mice · Bacterial therapy

Introduction

Squamous cervical cancer is the second most frequently occurring cancer in women worldwide, with over 200,000 deaths per year [1]. Despite advances in screening and treatment strategies, a significant number of patients die after first-line therapy. First-line chemotherapy for cervical cancer includes nanoparticle albumin-bound (nab)-paclitaxel (nab-PTX) [2]. Bevacizumab in combination with cisplatin–paclitaxel was approved as first-line therapy for advanced cervical cancer [3]. Minion et al. [4] have demonstrated that nab-PTX with bevacizumab could be used for recurrent cervical cancer after failing platinum–taxane or topotecan chemotherapy. Cediranib and pazopanib showed promise in advanced cervical cancer [5, 6]. In a Phase II

✉ Takuya Murata
t.muratactac@gmail.com

✉ Michael Bouvet
mbouvet@ucsd.edu

✉ Shree Ram Singh
singhshr@mail.nih.gov

✉ Itaru Endo
endoit@yokohama-cu.ac.jp

✉ Robert M. Hoffman
all@anticancer.com

Extended author information available on the last page of the article

trial, PTX together with nedaplatinum showed some promise for patients with advanced, recurrent, or metastatic cervical cancer [7]. Recently, chemo-radiation followed by PTX and carboplatinum was well tolerated in women with locally advanced cervical cancer [8]. However, there is no standard treatment option available for metastatic cervical cancer [9].

Clinically-relevant mouse models of cancer can be used for tailor-made therapy based on the patient-derived tumor. We established the patient-derived orthotopic xenograft (PDOX) nude mouse model for major tumor types [9–28], which has many advantages over subcutaneous transplant models [29].

Previously, we developed a tumor-targeting *Salmonella typhimurium* A1-R (*S. typhimurium* A1-R), which is auxotrophic for leu-arg [30]. *S. typhimurium* A1-R was effective in the PDOX models of many cancer types [18, 20–23, 26, 28].

We previously also developed a PDOX model of human epidermal growth factor receptor-2 (HER-2)-positive cervical cancer in which the most active regimen was the combination of tumor-targeting A1-R and trastuzumab [31]. In another cervical cancer PDOX model we previously developed, we demonstrated that nab-PTX was ineffective [9].

In the present study, we determined whether *S. typhimurium* A1-R could overcome nab-PTX resistance in a cervical cancer PDOX model.

Methods

Mice

In the present study, athymic nu/nu nude mice (AntiCancer Inc., San Diego, CA), 4–6 weeks old, were used. Animal housing, their diet, surgical procedures, and imaging were performed as previously described [23–25]. The response of animals during surgery was monitored to ensure adequate depth of anesthesia. The animals were observed daily and humanely sacrificed by CO₂ inhalation if they met the humane endpoint criteria as previously described [23–25]. All animal studies were conducted in accordance with the principles and procedures outlined in the National Institutes of Health Guide for the Care and Use of Animals under Assurance Number A3873-1.

Establishment of the cervical cancer PDOX model

The 57-year-old patient with primary cervical cancer previously received a radical hysterectomy with bilateral salpingo-oophorectomy and pelvic lymphadenectomy at Kawasaki Medical School Hospital, Japan [9]. The tumor was diagnosed as squamous cell carcinoma (grade 2). The patient did not receive any neoadjuvant therapy. Informed consent

was obtained, and PDOX studies were approved by the Institutional Ethics Committee of Kawasaki Medical School. A fresh resected tumor specimen was initially implanted subcutaneously in nude mice. The established tumors were cut into 5 mm³ fragments for surgical orthotopic implantation (SOI). A 6 mm lower abdominal midline incision was made under anesthesia. The neck of the uterus was exposed, and a single fragment was implanted by SOI using 8-0 nylon sutures (Ethicon, Inc., NJ, USA). The wound was closed with 6-0 PDS II (polydioxanone) sutures (Ethicon, Inc., NJ, USA) [23–25].

Preparation and administration of *S. typhimurium* A1-R

Salmonella typhimurium A1-R expressing green (GFP) (AntiCancer, Inc., San Diego, CA) was cultured in LB medium (Fisher Sci., Hanover Park, IL, USA) and then diluted 1:10 in LB medium. Bacteria were harvested at late-log phase, washed twice by PBS, and then diluted in PBS up to 5 × 10⁸ CFU/ml. *S. typhimurium* A1-R was administered by tail-vein injection. *S. typhimurium* A1-R (5 × 10⁷ CFU/100 μl) was injected in each mouse weekly [30, 31].

Treatment protocol for the cervical cancer PDOX model

The cervical cancer PDOX models were randomized into four groups when the tumor volume reached 60 mm³: G1: untreated group; G2: nab-PTX (i.v., 10 mg/kg, biweekly, 3 weeks); G3: *S. typhimurium* A1-R (i.v., 5 × 10⁷ CFU/body, weekly, 3 weeks); G4: nab-PTX combined with *S. typhimurium* A1-R (nab-PTX, 10 mg/kg, i.v., biweekly, 3 weeks; *S. typhimurium* A1-R 5 × 10⁷ CFU/body, i.v., weekly, 3 weeks). Each group comprised eight mice. All mice were sacrificed on day 22. Treatment doses, routes, and schedules were based on our previous reports [9]. Tumor volume and body weight were measured twice a week using the following formula: tumor volume (mm³) = length (mm) × width (mm) × width (mm) × 1/2. All mice were sacrificed on day 22.

Bacterial culture from tumor tissue

To demonstrate *S. typhimurium* A1-R tumor targeting, the cervical cancer PDOX tumors treated with *S. typhimurium* A1-R were resected on day 22 for bacteria culture. The tumor specimens were homogenized and suspended in 1 ml PBS. The suspension was diluted 10 times each up to 1:10,000, then cultured in LB agar medium for 12 h. *S. typhimurium* A1-R colonies expressing GFP were observed

with the OV100 Small Animal Imaging System (Olympus, Tokyo, Japan) [30, 31].

Histology

10% formalin-fixed, paraffin-embedded tissue sections (5 μ m) were deparaffinized in xylene and rehydrated in an ethanol series. H&E staining was performed using standard protocol. A BHS system microscope (Olympus Corp., Tokyo, Japan) was used for histological examination.

Statistical analysis

All statistical analyses were performed by statistical software EZR (Saitama Medical Center, Jichi Medical University), which is a graphical user interface for R (The R Foundation for Statistical Computing, version 3.4.1) [32]. It is a modified version of R commander (version 2.4–0) including statistical functions for biostatistics. A normal distribution was evaluated with the Shapiro–Wilk test. A Bartlett’s test was used to assess the homogeneity of variances across groups. One-way ANOVA with Tukey HSD for post hoc analysis was used for the parametric test for intergroup comparison. Kruskal–Wallis with Steel–Dwass for post hoc analysis was used for the non-parametric test to compare intergroup. Probability values of $P < 0.05$ were defined as statistical significance.

Results

Effect of treatment on tumor growth

The treatment protocol for the cervical cancer PDOX is shown in Fig. 1. Figure 2 illustrates the estimated tumor volume ratio (post-treatment/pre-treatment). Nab-PTX did not show significant efficacy compared to the control group ($P = 0.564$) as we have previously observed for this PDOX model [9]. There was also no significant difference between the *S. typhimurium* A1-R monotherapy group and the control group ($P = 0.121$). Nab-PTX combined with *S. typhimurium* A1-R was significantly effective compared to the untreated group ($P < 0.001$). Nab-PTX combined with *S. typhimurium* A1-R inhibited the tumor growth more than nab-PTX ($P = 0.026$). The final tumor volume ratios (day 22/day 0) were as follows: untreated control (G1) (5.52 ± 1.59); nab-PTX (G2) (4.63 ± 1.36); *S. typhimurium* A1-R (G3) (3.96 ± 1.03); nab-PTX combined with *S. typhimurium* A1-R (G4) (2.60 ± 0.98).

Effect of treatment on body weight

Body weight was compared in each group. The relative body weight (day 22/day 0) is shown in Fig. 3. No significant difference was observed between the four groups.




Fig. 1 Treatment protocol. G1: untreated group; G2: nab-PTX (i.v., 10 mg/kg, biweekly, 3 weeks); G3: *S. typhimurium* A1-R (i.v., 5×10^7 CFU/body, weekly, 3 weeks); G4: nab-PTX combined with *S.*

typhimurium A1-R (nab-PTX, 10 mg/kg, i.v., biweekly, 3 weeks; *S. typhimurium* A1-R, 5×10^7 CFU/body, i.v., weekly, 3 weeks). Each group comprised eight mice. All mice were sacrificed on day 22

Fig. 2 Efficacy of treatment on the tumor volume ratio. Bar graphs show tumor volume ratios (post-treatment/pre-treatment). Error bars: \pm SD. * $P < 0.05$, ** $P < 0.001$





Fig. 3 Effect of treatment on mouse body weight. Bar graphs show the body weight ratio of each group (post-treatment/pre-treatment). Error bars \pm SD

Targeting of *S. typhimurium* to the cervical cancer PDOX tumor

Targeting of *S. typhimurium* A1-R-GFP to the cervical cancer PDOX tumor was confirmed by culture in LB agar

medium of the homogenized PDOX tumor specimen previously treated with *S. typhimurium* A1-R, and subsequently Fluorescence Imaging (Fig. 4a, b).

Effect of treatment on tumor histology

Figure 5a–d are representative images of hematoxylin and eosin (H&E) staining of tumors from each group resected on day 22. Extensive proliferation of squamous cells was observed in the untreated group (Fig. 4a). The PDOX tumor faithfully replicated the original squamous-cell carcinoma as we reported previously [9]. Nab-PTX did not cause any noticeable histological changes (Fig. 4b). *S. typhimurium* A1-R monotherapy caused slight fibrotic changes (Fig. 4c). Nab-PTX combined with *S. typhimurium* A1-R caused extensive necrosis (Fig. 4d).

Discussion

Cervical cancer is a major problem that requires transformative therapeutic strategies. We have previously established PDOX nude mouse models of this disease and also demonstrated that the highly-touted agent, nab-paclitaxel (NAB-PTX) is ineffective for cervical cancer. Here we demonstrated that *S. typhimurium* A1-R combined with nab-PTX could overcome nab-PTX resistance in cervical cancer.




Fig. 4 Tumor targeting of *S. typhimurium* A1-R to the cervical-cancer PDOX tumor. Bright-field image (a) and fluorescence image (b) of GFP-expressing *S. typhimurium* A1-R colonies cultured in LB-

agar medium from PDOX tumors 24 h after the third treatment with *S. typhimurium* A1-R (day 23). Scale bars: 5 mm




Fig. 5 Effect of treatment on tumor histology. a Hematoxylin and eosin (H&E) staining of the untreated cervical-cancer PDOX tumor. b H&E staining of the cervical-cancer PDOX tumor treated with nab-PTX. c H&E staining of the *S. typhimurium* A1-R-treated cervical-

cancer PDOX tumor. d H&E staining of the cervical-cancer PDOX tumor treated with nab-PTX combined with *S. typhimurium* A1-R. A'–D' Show magnified images. Scale bar: 50 μ m

Various bacterial species such as *Salmonella*, *Listeria*, *Escherichia*, and *Clostridium* have been demonstrated to target and kill solid tumors. Among these bacteria, various strains of *Salmonella* colonize solid tumors and induce anti-tumor immunity [33, 34]. Yoon et al. [35] reported that

attenuated *S. typhimurium*-expressing recombinant IFN- γ invaded and directly killed melanoma cells and induced cytotoxicity rather than stable anti-tumor immunity [35].

Salmonella typhimurium A1-R has a number of different effects on tumors. Our previous experiments have shown that

S. typhimurium A1-R could kill cancer cells directly in vitro [30, 36, 37]. *S. typhimurium* A1-R destroys tumor vessels [38]. *S. typhimurium* A1-R also induces CD8+ T cells into the tumor [39]. *S. typhimurium* A1-R also decoys quiescent cancer cells to cycle from G₀/G₁ to S/G₂/M and makes cancer cells more sensitive to chemotherapy [40, 41]. Colonization of *S. typhimurium* at the tumor site resulted in an elevation of interleukin (IL)-1 β and tumor necrosis factor- α (TNF- α) within the tumor mass [42]. Further, a systematic injection of IL2-expressing *S. typhimurium* could reduce angiogenesis and increase necrosis within tumor tissues [43]. Therefore, tumor-targeting bacteria have great potential in treating solid tumors. Recently, we demonstrated that tumor-targeting *S. typhimurium* A1-R together with gemcitabine regresses partially GEM-resistant pancreatic cancer PDOX [44]. *Salmonella* LVR01 in combination with the toll-like receptor agonist, imiquimod, reduced tumor growth and prolonged survival in melanoma-bearing mice [45]. Wen et al. [46] demonstrated that TIMP-2 (tissue inhibitor of matrix metalloproteinases 2)-expressing *S. typhimurium* significantly inhibited tumor cell growth and enhanced animal survival, via down-regulating the expression of MMP-2 (matrix metalloproteinase-2).

In the present study, *S. typhimurium* A1-R did not show significant efficacy as a monotherapy. However, *S. typhimurium* A1-R combined with nab-PTX could overcome nab-PTX resistance.

Acknowledgements This paper is dedicated to the memory of A. R. Moossa, M.D., Sun Lee, M.D and Professor Li Jiayi.

Author contributions KM: Project development, data collection, data analysis, manuscript writing; TM, TM, MZ, TK, KK, KI, MM, TML, CH, SK, TK: data collection, data analysis; MB, KS, SRS, IE: data analysis; SRS : data analysis, manuscript writing and revision; RMH project development, data collection, data analysis, manuscript writing.

Compliance with ethical standards

Conflict of interest KM, TK, KK, KI, MM and RMH are or were unsalaried associates of AntiCancer, Inc. MZ is an employee of AntiCancer Inc.. CH, SK and TK are unsalaried associates of AntiCancer Japan. AntiCancer Inc. and AntiCancer Japan use PDOX models for contract reserach. There are no other competing commercial interests.

Ethical approval All animal studies were conducted in accordance with the principles and procedures outlined in the National Institutes of Health Guide for the Care and Use of Animals under Assurance Number A3873-1. For patient studies, an informed consent was obtained, and PDOX studies were approved by the Institutional Ethics Committee of Kawasaki Medical School.

References

- Wang CW, Wu TI, Yu CT et al (2009) Usefulness of p16 for differentiating primary pulmonary squamous cell carcinoma from cervical squamous cell carcinoma metastatic to the lung. *Am J Clin Pathol* 131:715–722
- Hashimoto K, Yonemori K, Katsumata N et al (2011) Use of squamous cell carcinoma antigen as a biomarker of chemotherapy response in patients with metastatic cervical carcinoma. *Eur J Obstet Gynecol Reprod Biol* 159:394–398
- Tewari KS, Sill MW, Long HJ et al (2014) Improved survival with bevacizumab in advanced cervical cancer. *N Engl J Med* 370:734–743
- Minion LE, Chase DM, Farley JH, Willmott LJ, Monk BJ (2016) Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study. *Gynecol Oncol Res Pract* 3:4
- Monk BJ, Pandite LN (2011) Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. *J Clin Oncol* 29:4845
- Symonds RP, Gourley C, Davidson S et al (2015) Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Oncol* 16:1515–1524
- Li Y, Zeng J, Huang M, An J, Bai P, Wu L, Zhang R (2017) A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma. *Cancer* 123(3):420–425
- Boardman CH, Brady WE, Dizon DS, Kunos CA, Moore KN, Zanotti KM, Matthews C, Cosin JA, Aghajanian C, Fracasso PM (2018) A phase I evaluation of extended field radiation therapy with concomitant cisplatin chemotherapy followed by paclitaxel and carboplatin chemotherapy in women with cervical carcinoma metastatic to the para-aortic lymph nodes: an NRG Oncology/ Gynecologic Oncology Group study. *Gynecol Oncol*. <https://doi.org/10.1016/j.ygyno.2018.08.006>
- Murakami T, Murata T, Kawaguchi K et al (2017) Cervical cancer patient-derived orthotopic xenograft (PDOX) is sensitive to cisplatin and resistant to Nab-paclitaxel. *Anticancer Res* 37:61–65
- Fu X, Le P, Hoffman RM (1993) A metastatic-orthotopic transplant nude mouse model of human patient breast cancer. *Anticancer Res* 13:901–904
- Fu X, Hoffman RM (1993) Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. *Anticancer Res* 13:283–286
- Wang X, Fu X, Hoffman RM (1992) A new patient-like metastatic model of human lung cancer constructed orthotopically with intact tissue via thoracotomy in immunodeficient mice. *Int J Cancer* 51:992–995
- Murakami T, Kiyuna T, Kawaguchi K et al (2017) The irony of highly effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years ago. *Cell Cycle* 16:1046–1052
- Fu X, Besterman JM, Monosov A et al (1991) Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. *Proc Natl Acad Sci USA* 88:9345–9349
- Metildi CA, Kaushal S, Luiken GA et al (2014) Fluorescently-labeled chimeric anti-CEA antibody improves detection and resection of human colon cancer in a patient-derived orthotopic xenograft (PDOX) nude mouse model. *J Surg Oncol* 109:451–458
- Furukawa T, Kubota T, Watanabe M et al (1993) Orthotopic transplantation of histologically intact clinical specimens of stomach cancer to nude mice: correlation of metastatic sites in mouse and individual patient donors. *Int J Cancer* 53:608–612
- Fu X, Guadagni F, Hoffman RM (1992) A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. *Proc Natl Acad Sci USA* 89:5645–5649

18. Hiroshima Y, Zhang Y, Murakami T et al (2014) Efficacy of tumor targeting *Salmonella typhimurium* A1-R in combination with antiangiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cell line mouse models. *Oncotarget* 5:12346–12357
19. Hiroshima Y, Maawy AA, Katz MH et al (2015) Selective efficacy of zoledronic acid on metastasis in a patient-derived orthotopic xenograft (PDOX) nude-mouse model of human pancreatic cancer. *J Surg Oncol* 111:311–315
20. Yamamoto M, Zhao M, Hiroshima Y et al (2016) Efficacy of tumor targeting *Salmonella typhimurium* A1-R on a melanoma patient derived orthotopic xenograft (PDOX) nude-mouse model. *PLoS One* 11:e0160882
21. Kawaguchi K, Igarashi K, Murakami T et al (2017) *Salmonella typhimurium* A1-R targeting of a chemotherapy resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide. *Cell Cycle* 16:1288–1294
22. Kawaguchi K, Igarashi K, Murakami T et al (2017) Tumor-targeting *Salmonella typhimurium* A1-R sensitizes melanoma with a BRAF-V600E mutation to vemurafenib in a patient-derived orthotopic xenograft (PDOX) nude mouse model. *J Cell Biochem* 118:2314–2319
23. Murakami T, DeLong J, Eilber FC et al (2016) Tumor-targeting *Salmonella typhimurium* A1-R in combination with doxorubicin eradicate soft tissue sarcoma in a patient-derived orthotopic xenograft PDOX model. *Oncotarget* 7:12783–12790
24. Igarashi K, Kawaguchi K, Murakami T et al (2017) High efficacy of pazopanib on an undifferentiated spindle-cell sarcoma resistant to first-line therapy is identified with a patient-derived orthotopic xenograft (PDOX) nude mouse model. *J Cell Biochem* 118:2739–2743
25. Igarashi K, Kawaguchi K, Kiyuna T et al (2017) Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. *Oncotarget* 8:75874–75880
26. Igarashi K, Kawaguchi K, Murakami T et al (2017) Intra-arterial administration of tumor-targeting *Salmonella typhimurium* A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. *Cell Cycle* 16:1164–1170
27. Kawaguchi K, Igarashi K, Murakami T et al (2017) Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model. *Cell Cycle* 16:1063–1069
28. Kiyuna T, Murakami T, Tome Y et al (2016) High efficacy of tumor-targeting *Salmonella typhimurium* A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model. *Oncotarget* 7:33046–33054
29. Hoffman RM (2015) Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. *Nat Rev Cancer* 15:451–452
30. Hoffman RM (2016) Bacterial therapy of cancer: methods and protocols. In: Walker JM (ed) *Methods in molecular biology* 1409. Humana Press, New York
31. Hiroshima Y, Zhang Y, Zhao M et al (2015) Tumor-targeting *Salmonella typhimurium* A1-R in combination with trastuzumab eradicates HER-2-positive cervical cancer cells in patient derived mouse models. *PLoS One* 10:e0120358
32. Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZ R' for medical statistics. *Bone Marrow Transplant* 48:452–458
33. Wang CZ, Kazmierczak RA, Eisenstark A (2016) Strains, mechanism, and perspective: *Salmonella*-based cancer therapy. *Int J Microbiol* 2016:5678702
34. Liang K, Liu Q, Li P, Luo H, Wang H, Kong Q (2019) Genetically engineered *Salmonella typhimurium*: recent advances in cancer therapy. *Cancer Lett* 448:168–181
35. Yoon W, Park YC, Kim J, Chae YS, Byeon JH, Min SH, Park S, Yoo Y, Park YK, Kim BM (2017) Application of genetically engineered *Salmonella typhimurium* for interferon-gamma-induced therapy against melanoma. *Eur J Cancer* 70:48–61
36. Zhao M, Yang M, Li XM et al (2005) Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing *Salmonella typhimurium*. *Proc Natl Acad Sci USA* 102:755–760
37. Nagakura C, Hayashi K, Zhao M, Yamauchi K (2009) Efficacy of a genetically-modified *Salmonella typhimurium* in an orthotopic human pancreatic cancer in nude mice. *Anticancer Res* 29:1873–1878
38. Liu F, Zhang L, Hoffman RM et al (2010) Vessel destruction by tumor-targeting *Salmonella typhimurium* A1-R is enhanced by high tumor vascularity. *Cell Cycle* 9:4518–4524
39. Murakami T, Hiroshima Y, Zhang Y et al (2018) Tumor-targeting *Salmonella typhimurium* A1-R promotes tumoricidal CD8(+) T cell tumor infiltration and arrests growth and metastasis in a syngeneic pancreatic-cancer orthotopic mouse model. *J Cell Biochem* 119:634–639
40. Yano S, Zhang Y, Zhao M et al (2014) Tumor-targeting *Salmonella typhimurium* A1-R decoys quiescent cancer cells to cycle as visualized by Fucci imaging and become sensitive to chemotherapy. *Cell Cycle* 13:3958–3963
41. Yano S, Takehara K, Zhao M et al (2015) Tumor-specific cell-cycle decoy by *Salmonella typhimurium* A1-R combined with tumor-selective cell-cycle trap by methioninase overcome tumor intrinsic chemoresistance as visualized by Fucci imaging. *Cell Cycle* 15:1715–1723
42. Kim JE, Phan TX, Nguyen VH, Dinh-Vu HV (2015) *Salmonella typhimurium* suppresses tumor growth via the pro-inflammatory cytokine interleukin-1 β . *Theranostics* 5:1328–1342
43. Al-Ramadi BK, Fernandez-Cabezudo MJ, El-Hasasna H, Al-Salam S, Bashir G, Chouaib S (2009) Potent anti-tumor activity of systemically-administered IL2-expressing *Salmonella* correlates with decreased angiogenesis and enhanced tumor apoptosis. *Clin Immunol* 130:89–97
44. Kawaguchi K, Miyake K, Zhao M, Kiyuna T, Igarashi K, Miyake M, Higuchi T, Oshiro H, Bouvet M, Unno M, Hoffman RM (2018) Tumor targeting *Salmonella typhimurium* A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models. *Cell Cycle* 17(16):2019–2026
45. Vola M, Monaco A, Bascuas T, Rimsky G, Agorio CI, Chabalgoity JA et al (2018) TLR7 agonist in combination with *Salmonella* as an effective antimelanoma immunotherapy. *Immunotherapy* 10:665–679
46. Wen M, Zheng JH, Choi JM, Pei J, Li CH, Li SY, Kim IY, Lim SH, Jung TY, Moon KS, Min JJ, Jung S (2018) Genetically-engineered *Salmonella typhimurium* expressing TIMP-2 as a therapeutic intervention in an orthotopic glioma mouse model. *Cancer Lett* 433:140–146

Affiliations

Kentaro Miyake^{1,2,3} · Takuya Murata⁴ · Takashi Murakami³ · Ming Zhao¹ · Tasuku Kiyuna^{1,2} · Kei Kawaguchi^{1,2} · Kentaro Igarashi^{1,2} · Masuyo Miyake^{1,2,3} · Thinzar M. Lwin² · Chihiro Hozumi⁵ · Shin Komatsu⁵ · Takashi Kikuchi⁵ · Michael Bouvet² · Koichiro Shimoya⁴ · Shree Ram Singh⁶  · Itaru Endo³ · Robert M. Hoffman^{1,2}

¹ AntiCancer Inc., San Diego, CA, USA

² Department of Surgery, University of California, San Diego, CA, USA

³ Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan

⁴ Department of Obstetrics and Gynecology, Kawasaki Medical School, Okayama, Japan

⁵ AntiCancer Japan Inc., Narita, Japan

⁶ Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA